Additional I/O target candidates identified by the Company’s predictive discovery platform. The Company is currently interrogating the platform to identify myeloid and lymphoid targets and others with complementary modes of action to checkpoint and myeloid inhibitors.
CGEN-15032 is a novel myeloid and epithelial immuno-oncology target. CGEN-15032 is expressed on cancer cells and subsets of myeloid cells within the tumor microenvironment. In vitro checkpoint activity for CGEN-15032 was demonstrated in human and mouse experimental systems. Tumor growth in CGEN-15032-deficient mice (knock-out mice) is reduced relative to wild-type mice, exemplifying its role in inhibiting anti-tumor immune response and potential to serve as a target for cancer immunotherapies. Treatment of CGEN-15032-deficient mice with an anti-PD-L1 antibody resulted in tumor growth inhibition as compared with anti-PD-L1 treated wild-type mice, indicating the combination potential of therapeutics targeting CGEN-15032 with PD1 pathway blockade. Together, these data suggest that CGEN-15032 may serve as an immuno-suppressive component of the tumor microenvironment, and that drugs inhibiting CGEN-15032 may activate anti-cancer immune responses.